Gaudium IVF FY26: Revenue Up 48%, Debtors Pay Slow
General information and entertainment, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Consult a registered adviser before acting.
1 — At a Glance
Gaudium IVF reported ₹104.4 Cr revenue in FY26, up 47.6% from ₹70.7 Cr in FY25. Net profit grew 28% to ₹24.5 Cr; operating margin: 36.1%. Thirty-plus locations operate on the hub-and-spoke model. The friction: debtors hit 187 days (from 170 in FY25), a structural working capital drag.
The fertility business has a peculiar rhythm — large upfront packages, long collection cycles. Profitable and fast-growing, recently IPO’d, the company scales expansion against a balance sheet where cash sits mainly in patient receivables.
Stock price: ₹105.75 (lagged reference).
2 — Introduction
Gaudium IVF operates India’s fertility clinic chain — 15 years old, founded by Dr. Manika Khanna, now operating 7 hubs and 28 spokes across Mumbai, Bangalore, Ludhiana, Patna, and Srinagar.
Listed Feb 27, 2026, raising ₹90 Cr fresh equity. IPO proceeds fund hub expansion (Delhi South, Gurgaon, Nagpur in FY27), debt repayment, and capex.
India’s fertility market is ART (Assisted Reproductive Technology): ~27.5 Mn infertile couples, ~300k IVF cycles annually. <2% penetration — room for expansion.
3 — Business Model: WTF Do They Even Do?
Revenue splits three ways: IVF treatment (64%), hospital services (4%), pharmacy (31% via subsidiary Gaudium International).
IVF treatment is the anchor — fixed packages averaging ₹2.98 lakh per patient. Patient journey: consultation, ovarian stimulation, egg retrieval (OPU), fertilization, transfer (ET), post-care. About 70% collected by OPU; remainder drizzles in as treatment progresses. This creates the debtors problem: clinics front costs, money dribbles back.
The hospital division (15-bed Delhi day-care) wraps post-delivery care. Pharmacy arm includes the acquired Gaudium Signature Labs testing franchise.
AI tools (SiD for sperm selection, ERICA for embryo grading) boost success rates — early data suggests 8–9% lift. Playbook: clinical excellence + tech + multi-channel marketing (50% digital, 30% brand, 20% word-of-mouth).
The Q4 results showed a sharp deceleration in growth — YoY revenue growth slowed to 12.7% from 29.4% in Q3 FY26 — a seasonal bruise or a portfolio shift, hard to call. Operating margin compressed to 40% in Q4 from 43% in Q3, signalling higher cost-of-service in the quarter.
Concall context: management attributed the Q4 slowdown to planned seasonality in fertility cycles and acceleration in capex spend for the two new Delhi hubs (South Delhi) launching in FY27. The company is at an inflection point — growth investments are eating into near-term margins.
5 — Market Expectations & Historical Multiples
This section describes how the market is currently pricing the company and how that compares with its own history and peer group. It is descriptive, not predictive.
Metric
Current
Peer Median
Historical Avg (3yr)
P/E
31.6x
46.9x
—
EV/EBITDA
20.6x
—
—
P/B
5.05x
6.05x
—
ROE
24.7%
19.75%
33.5%
ROCE
29.3%
22.28%
—
The market currently pays 31.6x annualized earnings, against a peer median of 46.9x across larger diagnostics and fertility platforms (Dr. Lal Pathlabs trades at 50x, Metropolis at 56x, Thyrocare at 54x). Gaudium sits below the peer average despite faster profit growth (28% YoY vs sector growth of 10–20%), suggesting the market is pricing in either caution about the fertility subsegment or execution risk on the expansion roadmap.
